Cutaneous adverse‐events in patients treated with Ibrutinib-Reference-Cited by-同舟云学术

Cutaneous adverse‐events in patients treated with Ibrutinib

Published:2020-09-27 Issue:6 Volume:33 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Pileri Alessandro¹^ORCID,Guglielmo Alba¹,Agostinelli Claudio²,Evangelista Valeria¹^ORCID,Bertuzzi Clara²,Alessandrini Aurora¹,Bruni Francesca¹,Starace Michela¹,Massi Alice¹,Broccoli Alessandro³,Patrizi Annalisa¹,Zinzani Pier Luigi³,Piraccini Bianca Maria¹

Affiliation:

1. Division of Dermatology Azienda Ospedaliero Universitaria di Bologna Bologna Italia

2. Division of Haematopathology Azienda Ospedaliero‐Universitaria di Bologna Bologna Italia

3. Division of Hematology Azienda Ospedaliero‐Universitaria di Bologna Bologna Italia

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14190

Reference30 articles.

1. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

2. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

3. Molecular Targeted Approaches in Mantle Cell Lymphoma

4. Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

5. Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is pustular psoriasis a potentially scarring dermatosis?;Italian Journal of Dermatology and Venereology;2024-04

2. Psoriasis: a new adverse event of ibrutinib;Italian Journal of Dermatology and Venereology;2024-04

3. Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia;Turkish Journal of Hematology;2024-03-04

4. Cutaneous Lymphocytic Vasculitis Due to Ibrutinib Therapy;Actas Dermo-Sifiliográficas;2024-02

5. Vascularite systémique sévère induite par l’ibrutinib;La Revue de Médecine Interne;2024-01